Introduction and Objective: Automated insulin delivery (AID) systems provide enhanced glycemic benefits and reduce diabetes care burden. We implemented a QI initiative aimed at increasing AID use in youth with new-onset T1D (<1 yr) at a large pediatric diabetes center from baseline of 5% in Jan 2022 to >25% by Nov 2024. As a balancing measure, we monitored for diabetic ketoacidosis (DKA) after AID initiation.Methods: The following Plan-Do-Study-Act cycles were implemented:1) Developed a standardized process for AID starts within 90 days of diagnosis, with a Pump Action Plan with back-up injection doses and ketone management.2) Added a 2-week post-diagnosis telemedicine visit with a provider and CDCES to assess AID eligibility.3) Hosted an “AID workshop” educating staff and providers.4) Standardized AID starts across 6 diabetes clinics, with weekly outreach by a CDCES and a post-pump provider visit within 30 days of initiation.5) Sent bulk patient portal messages informing patients about AID systems.Results: P-chart showed an increase in AID use in youth with new-onset T1D, with centerline shift from 13.9% to 33.4% by Nov 2024 (Figure 1). Only two had DKA out of 338 youth with new-onset T1D placed on pumps.Conclusion: Our QI efforts led to an increase in AID use in youth with new-onset T1D. Structured support and pump safety guidance may help mitigate the risk of DKA. Future studies should assess the glycemic impact of early AID initiation.
M. Vakharia: None. D.A. Buckingham: None. S. Lyons: None. D. DeSalvo: Consultant; Dexcom, Inc. Advisory Panel; Insulet Corporation. S. Mckay: None. S. Kelly: None. R.Y. Sonabend: None. G.K. Kim: None.
Source link
Leave a Reply